Prosecution Insights
Last updated: April 19, 2026
Application No. 17/785,929

A FERTILIZER GRANULE OF POLYHALITE AND POTASSIUM SULPHATE AND A COMPACTION PROCESS FOR THE PRODUCTION THEREOF

Final Rejection §103§DP
Filed
Jun 16, 2022
Examiner
LANGEL, WAYNE A
Art Unit
1736
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Icl Europe Cooperatief U A
OA Round
2 (Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
1275 granted / 1622 resolved
+13.6% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
46 currently pending
Career history
1668
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
33.6%
-6.4% vs TC avg
§102
2.0%
-38.0% vs TC avg
§112
37.6%
-2.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1622 resolved cases

Office Action

§103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-4, 8 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2018/229757 A1, for the reasons given in the last Office Action. Applicant’s argument, that the only detailed example of WO 2018/229757 A1 employs potash (KCl) - -not potassium sulfate – and does so without binder, is not convincing, since WO 2018/229757 A1 discloses in the sentence bridging pages 8 and 9, as well as claims 2 and 3, that potassium sulfate can be employed as the potassium source and with the addition of binder. Response to Arguments Applicant’s argument, that WO 2018/229757 A1 provides no teaching or expectations that polyhalite and potassium sulfate could be successively compacted together, let alone at the claimed ratio, is not convincing, since is only necessary that the reference fairly teach or suggestsdoing what applicant has done. Applicant’s argument, that the specific ratio of 1.1:0.9 between polyhalite and potassium sulfate was found to be critical for achieving mechanical stability, and that ratios outside this narrow range produce weak, friable granules, is not convincing, since there is no evidence on record to support such contention. Applicant’s argument, that WO 2018/229757 A1 provides no teaching or guidance as to selecting potassium silicate for compacting two specific materials – potassium sulfate and polyhalite – nor any indication of a critical narrow range of 1-2 % w/w, is not convincing, since WO 2018/229757 A1 discloses potassium silicate as a binder in the paragraph bridging pages 5 and 6, and further teaches on page 7, lines 16-18 that the binder is preferably present in a concentration between 1-5% w/w. Applicant’s argument, that WO 2018/229757 A1 discloses granule strength exceeding 2kgF per granule only after drying or curing, whereas applicant’s granules reach at least 2 kgF per granules immediately after production, is not convincing, since there is no evidence on record to support such contention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-4, 8 and 9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 10,934,225. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims would be obvious variants of the claims of US 10,934,225. Claims 1-4, 8 and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim s 1-8 of copending Application No. 17/785098. Although the claims at issue are not identical, they are not patentably distinct from each other because it would be obvious to determine suitable amounts of the potassium sulfate and polyhalite in the composition and method recited in the claims of 17/785098. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WAYNE A LANGEL whose telephone number is (571) 272-1353. The examiner can normally be reached Monday through Friday from 8:15 am to 4:15 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anthony Zimmer can be reached at 571-270-3591. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /WAYNE A LANGEL/Primary Examiner, Art Unit 1736 /WAYNE A LANGEL/Primary Examiner, Art Unit 1736
Read full office action

Prosecution Timeline

Jun 16, 2022
Application Filed
Jun 13, 2025
Non-Final Rejection — §103, §DP
Nov 16, 2025
Response Filed
Dec 05, 2025
Final Rejection — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599151
BIOCHARS, BIOCHAR EXTRACTS AND BIOCHAR EXTRACTS HAVING SOLUBLE SIGNALING COMPOUNDS AND METHOD FOR CAPTURING MATERIAL EXTRACTED FROM BIOCHAR
2y 5m to grant Granted Apr 14, 2026
Patent 12590043
COMPOSITIONS AND METHODS FOR IMPROVING PLANT GROWTH AND ABIOTIC STRESS TOLERANCE
2y 5m to grant Granted Mar 31, 2026
Patent 12583802
AUTONOMOUS DEVICE FOR IN-FIELD CONVERSION OF BIOMASS INTO BIOCHAR
2y 5m to grant Granted Mar 24, 2026
Patent 12583801
PROCESS FOR PRODUCING FERTILIZER FROM A BIOGAS STREAM
2y 5m to grant Granted Mar 24, 2026
Patent 12577179
Methods and Compositions for Soil Regeneration and Improved Soil Hydrology
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.3%)
2y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 1622 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month